➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Colorcon
Harvard Business School
Baxter
AstraZeneca

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DOVATO

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Dovato

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04553081 ↗ 2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial Recruiting ViiV Healthcare Phase 4 2020-05-26 The aim of this study is to monitor virological and immunological markers in participants who are switching from a classic triple drug regimen (3DR) to dual therapy (2DR). We aim to monitor whether this has an influence on different parameters such as severity of HIV disease (evaluated by viral load and viral reservoir size), presence of non-AIDS related health complications, impact the phenotype and function of the immune system. By conducting this study we want to assess whether switching from 3DR to 2DR implies an increased risk for 'subclinical' failure. We especially want to make sure that this switch does not increase the HIV reservoir, does not increase inflammation or immune exhaustion in patients living with HIV and that it can be considered as a safe long term alternative for the classic 3DR. The primary objective is to demonstrate non inferiority at W48 of the 2DR DTG/3TC (Dovato) regimen compared to BIC/TAF/FTC (Biktarvy) in terms of the amount of intact replication competent HIV sequences with a non-inferiority margin of 12% quantified by the fraction intact HIV viral sequences quantified by IPDA, present in blood CD4 cells.
NCT04553081 ↗ 2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial Recruiting University Hospital, Ghent Phase 4 2020-05-26 The aim of this study is to monitor virological and immunological markers in participants who are switching from a classic triple drug regimen (3DR) to dual therapy (2DR). We aim to monitor whether this has an influence on different parameters such as severity of HIV disease (evaluated by viral load and viral reservoir size), presence of non-AIDS related health complications, impact the phenotype and function of the immune system. By conducting this study we want to assess whether switching from 3DR to 2DR implies an increased risk for 'subclinical' failure. We especially want to make sure that this switch does not increase the HIV reservoir, does not increase inflammation or immune exhaustion in patients living with HIV and that it can be considered as a safe long term alternative for the classic 3DR. The primary objective is to demonstrate non inferiority at W48 of the 2DR DTG/3TC (Dovato) regimen compared to BIC/TAF/FTC (Biktarvy) in terms of the amount of intact replication competent HIV sequences with a non-inferiority margin of 12% quantified by the fraction intact HIV viral sequences quantified by IPDA, present in blood CD4 cells.
NCT04585737 ↗ Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF Recruiting ViiV Healthcare Phase 4 2020-09-22 Phase 4, randomized, open-label study to evaluate the efficacy, safety and tolerability of switching virologically suppressed adults living with HIV on bictegravir/tenofovir alafenamide/emtricitabine to dolutegravir/lamivudine
NCT04585737 ↗ Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF Recruiting Charlotte-Paige Rolle, MD Phase 4 2020-09-22 Phase 4, randomized, open-label study to evaluate the efficacy, safety and tolerability of switching virologically suppressed adults living with HIV on bictegravir/tenofovir alafenamide/emtricitabine to dolutegravir/lamivudine
NCT04826562 ↗ Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) Not yet recruiting ViiV Healthcare Phase 4 2021-04-01 An open-label, pilot study of switching patients to Dovato who are currently taking Bitarvy who are virological suppressed (HIV-1 < 50 copies/mL
NCT04826562 ↗ Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) Not yet recruiting Saint Michael's Medical Center Phase 4 2021-04-01 An open-label, pilot study of switching patients to Dovato who are currently taking Bitarvy who are virological suppressed (HIV-1 < 50 copies/mL
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dovato

Condition Name

Condition Name for Dovato
Intervention Trials
HIV-1-infection 2
HIV Infections 2
Human Immunodeficiency Virus 1
HIV Lipodystrophy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dovato
Intervention Trials
HIV Infections 3
Acquired Immunodeficiency Syndrome 2
Lipodystrophy 1
Infection 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dovato

Trials by Country

Trials by Country for Dovato
Location Trials
Italy 15
United States 2
Denmark 1
Belgium 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dovato
Location Trials
New Jersey 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dovato

Clinical Trial Phase

Clinical Trial Phase for Dovato
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dovato
Clinical Trial Phase Trials
Recruiting 4
Not yet recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dovato

Sponsor Name

Sponsor Name for Dovato
Sponsor Trials
ViiV Healthcare 4
Thomas Benfield 1
Saint Michael's Medical Center 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dovato
Sponsor Trials
Other 5
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Dow
Baxter
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.